Medical Communications
Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device
March 6, 2023 Medical Communications
Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and …
Elon Musk’s Neuralink rejected by FDA for human trials
March 3, 2023 Medical Communications
The FDA has reportedly rejected a bid by Elon Musk’s Neuralink in which they proposed the initiation of human testing …
FDA grants orphan drug designation to Temferon for glioblastoma multiforme
March 3, 2023 Medical Communications
The FDA has granted Temferon an Orphan Drug Designation (ODD) for use as a therapeutic option for patients with glioblastoma …
A gene test could guide decisions around chemotherapy for bowel cancer
March 3, 2023 Medical Communications
Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene …
Microba Life Sciences launches next-generation healthcare testing for gastrointestinal health
March 2, 2023 Medical Communications
Australian precision microbiome company Microba Life Sciences has launched its next-generation testing range for gastrointestinal health. MetaXplore has been relaunched …
Eli Lilly caps consumer insulin costs at $35
March 2, 2023 Medical Communications
Eli Lilly & Co has announced that it will cap out-of-pocket insulin costs at $35 per month, following a plea …
FDA panel backs GSK RSV vaccine ahead of approval
March 2, 2023 Medical Communications
Yesterday, GSK shared that an advisory committee from the FDA voted in support of its respiratory syncytial virus (RSV) vaccine …
NICE recommends more digital mental health therapies for NHS use
March 1, 2023 Medical Communications
Eight more digital therapies (DTx) for mental health disorders have been recommended by NICE for use by the NHS, following …
FDA approves Reata Pharmaceuticals’ first-in-class treatment for Friedreich’s Ataxia
March 1, 2023 Medical Communications
US-based Reata Pharmaceuticals has announced that its first-in-class treatment for Friedreich’s Ataxia (FA), Skyclarys, has been given FDA approval. This …
Johnson & Johnson’s Janssen-Cilag unit gets disappointing ‘restricted’ label for PARP drug in EU
February 28, 2023 Medical Communications
Johnson & Johnson (J&J)’s Janssen-Cilag unit has announced that its fixed-dose combination drug Akeega has been recommended for approval by …
MHRA’s authority restored following Northern Ireland Brexit deal
February 28, 2023 Medical Communications
The Medicines and Healthcare products Regulatory Agency (MHRA) has been limited to approving medicines in Great Britain (England, Scotland and …
FDA sued by US states over abortion pill access
February 27, 2023 Medical Communications
Attorneys general (AGs) from 12 Democrat-led US states have made complaints to the FDA in an attempt to force the …
Causeway Therapeutics raises £8.75m for tennis elbow research
February 27, 2023 Medical Communications
University of Glasgow spin-out Causeway Therapeutics has announced that it has raised £8.75m from investors, which will fund an international …
AbbVie gains positive CHMP opinion for upadacitinib for the treatment of Crohn’s disease
February 27, 2023 Medical Communications
AbbVie has announced that it has received positive feedback from the EMA’s Committee for Medicinal Products for Human Use (CHMP) …
Merck to appeal EU rejection of COVID-19 drug
February 27, 2023 Medical Communications
Life science giant Merck & Co has announced that it will appeal the EU’s Committee for Medicinal Products for Human …
Latest content
October 26, 2026
